StockWatch
·
AKUMS DRUGS AND PHARMACEUTICALS LTD · QQ2 FY-2027 · THE CALL

Strong CDMO, margins held; near-term capex & Zambia slip limit upside

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q2 FY27 resultsAKUMSAkums Drugs and Pharmaceuticals Ltd05 Nov 2026 · 6 min read
Verdict

Hold

confidence 7/10

Credibility

Grade B

Met CDMO growth (20%+ vs high-teens), margin guidance (14.5% in 14–15% band), but Zambia pushed Q4→Q1 due to elections.

Short-term outlook

Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Q2 delivered on CDMO momentum (31.9% revenue, 20%+ volume growth) and margin discipline (14.5%), but near-term catalysts (Baddi capex, Zambia delayed from H2 to Q1 FY28) and API overhang limit upside. Long-term CDMO trajectory intact; short-term execution risk elevated.

₹1342 Cr

Revenue · +31.9% YoY

₹115 Cr

Reported PAT · +168.3% YoY

Expanding

Margins · vs guidance: Corroborated

Did the claims hold up?

Management's claims vs. the numbers

Double-digit volume growth during quarter

MET

CDMO volume +20% on September net MAT basis; Sept revenue growth 15.6% QoQ

EBITDA more than doubled YoY

MET

₹195 Cr vs ₹94-95 Cr Q2 FY26 = 106% growth

Quarter-on-quarter revenue growth stood at impressive 15%

MET

Revenue ₹1,018 Cr (Q1) to ₹1,342 Cr (Q2) = 15.1% QoQ

Zambia business ~₹240 Cr in H2 FY27

OVERSTATED

Supplies scheduled Q4; revenue booking Q1 FY28 due to election delays

CDMO high-teens volume growth Q2-onwards

MET

Delivered 20%+ volume growth on net MAT basis

Earnings quality

What changed since the last call

Deltas vs. the prior call

Zambia revenue timing

Downgrade

Prior call: ~₹240 Cr H2 FY27. Now: Q4 FY27 supplies → revenue Q1 FY28 (election-related delay 3 months).

CDMO volume growth

Upgrade

Guidance high-teens; delivered 20%+ on net MAT. Sept 50%+ utilization vs prior steady-state talk.

API trajectory

Neutral

Loss ₹5.7 Cr EBITDA (vs ₹14 Cr Q2 FY26). Path to breakeven confirmed by end FY27; no acceleration claimed.

EBITDA margin guidance

Maintained

14–15% target reaffirmed. Q2 landed 14.5% (lower end of range); management says upper bracket bias remains as Baddi scales.

Baddi plant scale-up

New

Phase 1 oral solids 6B units/annum, fully operational Q1 FY28. Expected to deliver 10–15% of CDMO business in 3 years.

The Q&A

Analysts pressed hard on Zambia delay (Saksham Tyagi: credible answer on elections → supplies Q4), European path (questioned dossier approval timeline → 1–2 quarters, realistic), API segment (asked for breakeven timeline → 3–4 quarters, tracked), and Baddi capex phasing (Tyagi & Bhuva: got detailed answers on cost & funding flexibility). Management held firm; no dodging.

The exchanges that mattered

Zambia & Europe execution — Saksham Tyagi, Desvelado Advisory

Answered

Zambia: midyear elections delayed govt procurement; now received PO, Q4 supplies → Q1 revenue booking. Europe: dossier filed, approval 1–2 quarters expected.

Baddi capex & timeline — Saksham Tyagi, Desvelado Advisory

Answered

Phase 1 (6B oral solids) ₹43 Cr capex, operational Q1 FY28. Flexible on debt/internal funds; capex 3x turn on gross margin.

API segment outlook — Saksham Tyagi, Desvelado Advisory

Partial

Loss ₹5.7 Cr EBITDA vs ₹14 Cr prior year. No line yet. Endeavor is 3–4 quarters to breakeven. Focus on product mix & geographies.

Domestic branded growth & PCPM — Vansh Gupta, Prescient Capital

Answered

No specific guidance. Growth is 8% YoY. PCPM 2.5 for business; therapies (esp. gynae 40–45% of rev) mature. New 200 field force hires dragged PCPM down temporarily.

CDMO therapeutic areas driving growth — Vansh Gupta, Prescient Capital

Partial

Therapies growth across contract mfg, existing & new customers, all forms. No specific therapy skew. Fair share in Indian market. R&D upward 3% of CDMO revenue.

Oriflame acquisition contribution — Divya Daga, Vijit Global Securities

Answered

Bought for ₹56 Cr (color cosmetics entry). Peak 3x revenue expected over couple of years; minimal PAT contribution this year as ramp phase.

Baddi facility timeline & capex phasing — Divya Daga, Vijit Global Securities

Answered

Phase 1 (6B units oral solids) operationalizes Q1 FY28. Expected 10–15% of CDMO business 3 years out. Capex phased as maturity achieved.

Oreflame ROI & Baddi payback — Meet Bhuva, Entrigity Ventures & Partnerships

Answered

Flexible funding: loans available at lower cost; will use own funds if beneficial. Capex historically 3x turn on gross margin.

CDMO pricing power & API prices — Axay Shah, VVD Asset Managers

Answered

API prices up 2–3% QoQ (vs 5–7% last Q2 FY26). Slight upward trajectory only; commodities-dependent. Q4 onwards pricing uncertain.

R&D expense & R&D headcount — Praveen Jayaraman, Avendus Spark Institutional Equities

Answered

Broadly 3% of revenue (₹130–odd crore). Upward 3–3.5% for regulated markets. Manpower: 375 scientists, 100-odd support staff.

Major contract pipeline — Praveen Jayaraman, Avendus Spark Institutional Equities

Dodged

Nothing disclosed as of now. Rest over here. Endeavor remains how do we grow the business.

Domestic branded growth drivers & margin path — Sangeeta Purushottam, Cogito Advisors

Answered

CDMO fast-growing, 56–57 rank in India (almost 90–92% revenue from India). Manpower investment (450 hires on sales force) dragged EBITDA. Path forward: higher PCPM (above 3), new product launches (half of growth).

Trade generics exit strategy — Sangeeta Purushottam, Cogito Advisors

Answered

Trade generics was historical (₹400-odd Cr at peak); now ₹56–57 Cr rank. Kepts pockets profitable, lean structure. No discontinuation of branded play. Tier 4 geographies, distributor network kept lean; not losing money.

Guidance

Forward guidance and management's confidence

No explicit FY27/FY28 revenue target; CDMO high-teens vol growth (Q2 delivered 20%+)

High

CDMO +38.6% YoY on strong underlying volumes; utilization 50%+; IPM penetration expanding.

Maintain 14–15% EBITDA margin; bias toward upper bracket

High

Q2 delivered 14.5% (within band). Baddi ramp & API breakeven expected to support margin lift post-Q1 FY28.

H1 capex ₹210 Cr (Oreflame ₹56 Cr + Baddi ramp); flexible debt/equity funding

Medium

Baddi phase 1 ₹43 Cr; phases 2–3 TBD. Company targeting 3x turn on gross margin; no specific guidance for FY27/28 total capex.

Risks the call surfaced

Ranked by how much they should concern a holder

CDMO customer concentration

Medium

CDMO ₹1,115 Cr (83% of revenue). Volume growth 20%+ driven by existing & new customers, but no single-customer exposure detail given.

Zambia execution delay

Medium

Prior guidance ₹240 Cr H2 FY27; now Q4 FY27 supplies → Q1 FY28 revenue (100–120 day shipping lag + earlier election delays).

API segment ongoing losses

Medium

API EBITDA loss ₹5.7 Cr Q2 (vs ₹14 Cr prior year). Breakeven dependent on product mix optimization & price recovery (commodities-volatile).

Baddi capex concentration & ramp risk

Medium

₹43 Cr capex in H1 FY27 for Baddi phase 1 (6B units oral solids). Operationalization Q1 FY28; margin support contingent on utilization ramp.

Domestic branded growth headwind

Low

Domestic branded only 8% YoY; PCPM 2.5 due to 450 new field force hires. IPM-pace growth guidance implies mid-single digit outlook.

Management

Score 7/10. Clear on business segments & drivers; transparent on Zambia delays (election-blamed). Cautious on near-term; no vague promises. Detailed on capex phasing & R&D. Met CDMO guidance (20%+ vol growth vs high-teens prior). Margin on target (14.5% in 14–15% band). Zambia timing slip but PO in hand. API improving (loss ₹14 Cr → ₹5.7 Cr).

What to watch next
  • 1 · Q1 FY28

    Baddi phase 1 operationalizes; Zambia supplies booked; API approaches breakeven

  • 2 · H2 FY28

    European CDMO supplies commence; Baddi phases 2–3 ramp begin

  • 3 · Q4 FY27

    Zambia supplies dispatched (100–120 days shipping lag); margin cushion from higher-margin CDMO

Long-term CDMO trajectory intact; short-term execution risk elevated.

Informational and educational content only. Not investment advice.